Full-year numbers for Hutchison China Meditech (HCM) remain of secondary importance to clinical development. The bio-pharma group closed out 2019 with $17.6m (£13.5m) in sales linked to its Elunate (colorectal cancer) product, with the prospect of multiple global registration studies this year, and the further development of eight clinical drug candidates, five of which are globally focused. Clinical development comes at a cost, with eventual returns uncertain or long-dated. So, the net loss from the innovation platform attributable to Chi-Med was up by over a quarter year on year to $133m.
IC TIP:
Buy
at
380p